[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 173
71. Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y: Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell; 2009 Jun 2;15(6):514-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.
  • However, the mechanisms by which alterations of these glioblastoma genes singly and cooperatively transform brain cells remain poorly understood.
  • By targeting a p53 in-frame deletion mutation to the brain, we show that p53 deficiency provides no significant growth advantage to adult brain cells, but appears to induce pleiotropic accumulation of cooperative oncogenic alterations driving gliomagenesis.
  • Our data show that accumulation of a detectable level of mutant p53 proteins occurs first in neural stem cells in the subventricular zone (SVZ) and that subsequent expansion of mutant p53-expressing Olig2(+) transit-amplifying progenitor-like cells in the SVZ-associated areas initiates glioma formation.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2121-7 [8668337.001]
  • [Cites] J Neurosci. 1997 Jul 1;17(13):5046-61 [9185542.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Nat Neurosci. 2005 Jul;8(7):865-72 [15951811.001]
  • [Cites] Development. 2005 Dec;132(24):5577-88 [16314489.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1107-16 [16436596.001]
  • [Cites] Mol Cell. 2006 Jun 23;22(6):741-53 [16793544.001]
  • [Cites] J Neurosci. 2006 Jul 26;26(30):7907-18 [16870736.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):704-9 [17046226.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):424-9 [17622647.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Neuron. 2008 Jun 26;58(6):832-46 [18579075.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] Int J Oncol. 2003 Sep;23(3):641-8 [12888899.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3525-32 [15150107.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • (PMID = 19477430.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS053900-03; United States / NINDS NIH HHS / NS / R01 NS053900; United States / NINDS NIH HHS / NS / 1R01 NS053900; United States / NINDS NIH HHS / NS / R01 NS053900-01; United States / NINDS NIH HHS / NS / NS053900-01; United States / NINDS NIH HHS / NS / R01 NS053900-02; United States / NINDS NIH HHS / NS / NS053900-02; United States / NINDS NIH HHS / NS / R01 NS073762; United States / NINDS NIH HHS / NS / NS053900-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS112275; NLM/ PMC2721466
  •  go-up   go-down


72. Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK, US Pediatric Brain Tumor Consortium: Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol; 2008 Jun;10(3):265-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.
  • Human malignant glioma cell lines and adult brain tumors overexpress high levels of interleukin-13 receptor alpha2 chain (IL-13Ralpha2).
  • Because the IL-13Ralpha2 chain is an important target for cancer therapy and prognosis for patients with brainstem glioma (BSG) remains dismal, we investigated the expression of this receptor in specimens of diffusely infiltrative pediatric BSG relative to normal brain tissue.
  • Twenty-eight BSG specimens and 15 normal brain specimens were investigated for IL-13Ralpha2 protein expression by immunohistochemical analysis (IHC) using two different antibodies in two different laboratories.
  • By Q-dot IHC or a standard IHC assay, 17 of 28 (61%) tumor specimens showed modest to strong staining for IL-13Ralpha2, while 15 normal brain tissue samples showed weak expression for IL-13Ralpha2 protein.
  • High-level IL-13Ralpha2 RNA expression was detected in tumor samples by Q-dot ISH, but only weak RNA expression was observed in normal brain.
  • IL-13Ralpha2 protein and mRNA are expressed to significantly higher levels in BSG than in normal brain tissue.

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2000 Sep 1;11(13):1829-35 [10986556.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3506-13 [10828036.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6194-200 [11507072.001]
  • [Cites] Cancer Gene Ther. 2001 Nov;8(11):861-8 [11773976.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1103-9 [11861389.001]
  • [Cites] Oncol Res. 2001;12(11-12):459-67 [11939409.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3431-7 [12177103.001]
  • [Cites] J Immunol. 2002 Dec 15;169(12):7119-26 [12471149.001]
  • [Cites] J Exp Med. 2003 Mar 17;197(6):703-9 [12642602.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):37-48 [14649884.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1036-42 [15329913.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):2200-5 [2005905.001]
  • [Cites] J Neurosurg. 1993 Oct;79(4):569-76 [7692018.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):574-81 [8056454.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8797-804 [7721786.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):16775-80 [7622490.001]
  • [Cites] J Immunol. 1996 Apr 15;156(8):2972-8 [8609418.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22428-33 [8798406.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):185-92 [8873160.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5631-7 [8971168.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):756-64 [8992992.001]
  • [Cites] Mol Med. 1997 May;3(5):327-38 [9205948.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3272-80 [9242460.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):20251-8 [9242704.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):948-53 [9258124.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):90-4 [9299458.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Int Immunol. 1998 Aug;10(8):1103-10 [9723696.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1253-8 [9815919.001]
  • [Cites] Clin Cancer Res. 1997 Feb;3(2):151-6 [9815666.001]
  • [Cites] Int J Mol Med. 1998 Mar;1(3):551-7 [9852261.001]
  • [Cites] Biophys J. 1999 Jul;77(1):154-72 [10388747.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2956-63 [15805299.001]
  • [Cites] Nat Med. 2006 Jan;12(1):99-106 [16327802.001]
  • [Cites] Technol Cancer Res Treat. 2006 Jun;5(3):239-50 [16700620.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3145-51 [16707614.001]
  • [Cites] Vitam Horm. 2006;74:479-504 [17027527.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):837-44 [17327604.001]
  • [Cites] Int J Hematol. 1999 Jan;69(1):13-20 [10641437.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):168-75 [11291041.001]
  • (PMID = 18430795.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2563049
  •  go-up   go-down


73. Lázaro BC, Landeiro JA: Tectal plate tumors. Arq Neuropsiquiatr; 2006 Jun;64(2B):432-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tectal plate is a rare location for a tumor.
  • Open surgery was performed in three cases (due to tumor enlargement or need for the exact diagnosis).
  • In our series, except in the metastatic tumor case and the cavernoma, the other types of lesion consisted of low grade gliomas.
  • These lesions represent a different type of brain stem tumor sharing a common good prognosis, with a benign behavior.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis. Tectum Mesencephali
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917614.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


7
Advertisement
4. Sanai N, Wachhorst SP, Gupta NM, McDermott MW: Transcerebellar stereotactic biopsy for lesions of the brainstem and peduncles under local anesthesia. Neurosurgery; 2008 Sep;63(3):460-6; discussion 466-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcerebellar stereotactic biopsy for lesions of the brainstem and peduncles under local anesthesia.
  • OBJECTIVE: For certain brainstem lesions, a diagnostic biopsy is required for treatment planning.
  • METHODS: We retrospectively reviewed hospital records for all adult patients with symptomatic lesions of the pons and/or cerebellar peduncle who underwent an awake transcerebellar stereotactic biopsy at our institution over a 7-year period.
  • Diagnoses in the 13 cases included infiltrative glioma (), metastases (), lymphoma (), encephalitis (), and reactive astrogliosis ().
  • CONCLUSION: Tissue diagnosis of lesions in the brainstem and cerebellar peduncles continues to be a significant challenge, with the potential for major morbidity.
  • [MeSH-major] Anesthesia, Local / methods. Brain Stem / pathology. Brain Stem Neoplasms / diagnosis. Cerebellum / pathology. Stereotaxic Techniques. Tegmentum Mesencephali / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812957.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Gaviani P, Gonzalez RG, Zhu JJ, Batchelor TT, Henson JW: Central neurogenic hyperventilation and lactate production in brainstem glioma. Neurology; 2005 Jan 11;64(1):166-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurogenic hyperventilation and lactate production in brainstem glioma.
  • [MeSH-major] Brain Stem Neoplasms / complications. Brain Stem Neoplasms / metabolism. Glioma / complications. Glioma / metabolism. Hyperventilation / etiology. Lactic Acid / metabolism
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642931.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid
  •  go-up   go-down


86. Ree A, Jain R, Rock J, Rosenblum M, Patel SC: Direct infiltration of brainstem glioma along the cranial nerves. J Neuroimaging; 2005 Apr;15(2):197-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct infiltration of brainstem glioma along the cranial nerves.
  • The authors describe a case of a low-grade brainstem glioma extending along the cranial nerves without any evidence of leptomeningeal spread.
  • The tumor extended directly along the VII-VIIIth cranial nerve complex and also along the trigeminal nerve, which is quite an unusual characteristic of the glial tumors.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Cranial Nerve Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Adult. Facial Nerve Diseases / pathology. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Trigeminal Nerve Diseases / pathology. Vestibulocochlear Nerve Diseases / pathology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746234.001).
  • [ISSN] 1051-2284
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kansal R, Mahore A, Goel A: Cerebrospinal fluid rhinorrhea after ventriculoperitoneal shunt in a patient with tectal plate glioma. J Clin Neurosci; 2010 Apr;17(4):532-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid rhinorrhea after ventriculoperitoneal shunt in a patient with tectal plate glioma.
  • Cerebrospinal fluid (CSF) rhinorrhea due to a remote tumor is a rare but increasingly reported condition, where it is usually a presenting complaint.
  • CSF rhinorrhea occurring after tumor decompression has also been reported.
  • We report a patient with tectal plate glioma that caused CSF rhinorrhea following insertion of ventriculoperitoneal shunt.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Cerebrospinal Fluid Rhinorrhea / etiology. Glioma / pathology. Ventriculoperitoneal Shunt / adverse effects
  • [MeSH-minor] Humans. Hydrocephalus / etiology. Hydrocephalus / surgery. Magnetic Resonance Imaging. Male. Tectum Mesencephali / pathology. Tectum Mesencephali / surgery. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096589.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


88. Ayuso-Sacido A, Graham C, Greenfield JP, Boockvar JA: The duality of epidermal growth factor receptor (EGFR) signaling and neural stem cell phenotype: cell enhancer or cell transformer? Curr Stem Cell Res Ther; 2006 Sep;1(3):387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The duality of epidermal growth factor receptor (EGFR) signaling and neural stem cell phenotype: cell enhancer or cell transformer?
  • Recruitment of neural stem cells (NSCs) represents an elegant strategy for replacing adult central nervous system (CNS) cells lost to injury or disease.
  • However, except in the rostral migratory stream to the olfactory bulb, the adult CNS harbors a relatively non permissive environment for motility of neural stem cells.
  • This opens the possibility of therapeutic enhancement of NSC motility towards sites of CNS injury or disease.
  • Recent evidence supports the theory that GBM derives from a 'cancer stem cell' and that EGFR signals are commonly altered in these precursor cells.
  • This article will review the role of EGFR signaling as it relates to neural stem cell motility and invasion.
  • The duality of altered EGFR signaling in neural progenitor cells is discussed and opportunities for enhancing the recruitment of adult progenitors, and consequences of altering EGFR signaling in progenitor cells will be highlighted.
  • [MeSH-major] Brain Neoplasms / therapy. Neurons / cytology. Neurons / physiology. Receptor, Epidermal Growth Factor / physiology. Signal Transduction / physiology. Stem Cell Transplantation. Stem Cells / cytology. Stem Cells / physiology
  • [MeSH-minor] Adult. Glioma / pathology. Glioma / physiopathology. Glioma / therapy. Humans. Phenotype. Receptor Cross-Talk

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220882.001).
  • [ISSN] 1574-888X
  • [Journal-full-title] Current stem cell research & therapy
  • [ISO-abbreviation] Curr Stem Cell Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 87
  •  go-up   go-down


89. Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, Cohen K, Speights RA, Wright J, Pollack IF, Children's Oncology Group: A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer; 2007 Dec 1;110(11):2535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
  • BACKGROUND: An open-label Phase II study of tipifarnib was conducted to evaluate its safety and efficacy in children with recurrent or refractory medulloblastoma (MB)/primitive neuroectodermal tumor (PNET), high-grade glioma (HGG), and diffuse intrinsic brainstem glioma (BSG).
  • CONCLUSIONS: Tipifarnib tolerated well but had little activity as a single agent in children with recurrent central nervous system malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Medulloblastoma / drug therapy. Quinolones / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Female. Humans. Male. Neuroectodermal Tumors / drug therapy. Treatment Outcome


90. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Jun 20;28(18):3069-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG).
  • Toxicities related to BVZ included grade 1 to 3 fatigue in seven patients, grade 1 to 2 hypertension in seven patients, grade 1 CNS hemorrhage in four patients, and grade 4 CNS ischemia in two patients.
  • CONCLUSION: BVZ plus CPT-11 was well-tolerated but had minimal efficacy in children with recurrent malignant glioma and brainstem glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Child. Diffusion Magnetic Resonance Imaging. Humans. Phosphorylation. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):309-16 [18337733.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):624-30 [18539884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9 [18793954.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 [12972536.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6 [15552623.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):172-87 [15687360.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2347-55 [15985545.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • (PMID = 20479404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2903337
  •  go-up   go-down


91. Takarada T, Yoneda Y: Transactivation by Runt related factor-2 of matrix metalloproteinase-13 in astrocytes. Neurosci Lett; 2009 Feb 20;451(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown functional expression by osteoblasts of signaling machineries required for neurotransmission in the brain.
  • In this study, we have evaluated possible functional expression of different osseous genes in the brain.
  • In embryonic and adult mouse brains, mRNA expression was invariably seen for the master regulator of osteoblastic differentiation Runt related factor-2 (Runx2), in addition to the partner protein core binding factor-beta and their targets such as osteopontin (OPN) and matrix metalloproteinase-13 (MMP13), but not for collagen-I or osteocalcin.
  • Both mRNA and corresponding protein were detected for Runx2 in cultured rat neocortical astrocytes and astrocytic C6 glioma cells.
  • In C6 glioma cells, transient overexpression of Runx2 significantly increased mRNA expression of MMP13, but not of OPN.
  • Moreover, transient overexpression of Runx2 significantly increased luciferase activity in C6 glioma cells transfected with the reporter plasmid linked to a wild-type Runx2 binding element in the MMP13 promoter, but not in cells with a mutated element.
  • [MeSH-major] Astrocytes / metabolism. Brain / metabolism. Core Binding Factor Alpha 1 Subunit / genetics. Core Binding Factor Alpha 1 Subunit / metabolism. Matrix Metalloproteinase 13 / genetics. Transcriptional Activation / genetics
  • [MeSH-minor] Animals. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Line, Tumor. Core Binding Factor beta Subunit / genetics. Core Binding Factor beta Subunit / metabolism. Gene Expression Regulation, Enzymologic / genetics. Glial Fibrillary Acidic Protein / analysis. Glial Fibrillary Acidic Protein / metabolism. Glioma / genetics. Glioma / metabolism. Luciferases / genetics. Mice. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / metabolism. Osteopontin / genetics. Osteopontin / metabolism. Pluripotent Stem Cells / metabolism. Promoter Regions, Genetic / genetics. Rats. Signal Transduction / genetics. Transfection

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121369.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cbfb protein, mouse; 0 / Core Binding Factor Alpha 1 Subunit; 0 / Core Binding Factor beta Subunit; 0 / Glial Fibrillary Acidic Protein; 0 / Microtubule-Associated Proteins; 0 / Mtap2 protein, rat; 0 / Runx2 protein, rat; 0 / Spp1 protein, rat; 106441-73-0 / Osteopontin; EC 1.13.12.- / Luciferases; EC 3.4.24.- / Matrix Metalloproteinase 13; EC 3.4.24.- / Mmp13 protein, rat
  •  go-up   go-down


92. Germano I, Swiss V, Casaccia P: Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link? Neuropharmacology; 2010 May;58(6):903-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link?
  • The discovery of brain tumor-derived cells (BTSC) with the properties of stem cells has led to the formulation of the hypothesis that neural stem cells could be the cell of origin of primary brain tumors (PBT).
  • In this review we present the most common molecular changes in PBT, define the criteria of identification of BTSC and discuss the similarities between the characteristics of these cells and those of the endogenous population of neural stem cells (NPCs) residing in germinal areas of the adult brain.
  • Finally, we propose possible mechanisms of cancer initiation and progression and suggest a model of tumor initiation that includes intrinsic changes of resident NSC and potential changes in the microenvironment defining the niche where the NSC reside.

  • Genetic Alliance. consumer health - Brain Stem Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [Cites] Lab Invest. 2002 Nov;82(11):1481-92 [12429808.001]
  • [Cites] J Cell Biochem. 2003 Jan 1;88(1):11-9 [12461769.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):644-8 [12548606.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7331-6 [12777630.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):145-57 [15013214.001]
  • [Cites] Dev Biol. 2004 Jun 15;270(2):488-98 [15183728.001]
  • [Cites] Histopathology. 2004 Jun;44(6):555-60 [15186270.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4783-9 [15256447.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Acta Neuropathol. 1979 Mar 15;45(3):167-75 [442982.001]
  • [Cites] Neurosurgery. 1980 Nov;7(5):435-9 [6255368.001]
  • [Cites] Lancet. 1982 Apr 17;1(8277):885-7 [6122104.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(8):2390-4 [6572982.001]
  • [Cites] Tumori. 1986 Apr 30;72(2):163-70 [3705189.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]
  • [Cites] J Neurosci. 1992 Nov;12(11):4565-74 [1432110.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4130-40 [9307304.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):193-209 [9440020.001]
  • [Cites] Cell. 1999 Jan 8;96(1):25-34 [9989494.001]
  • [Cites] Cell Death Differ. 2006 Jul;13(7):1238-41 [16456578.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8655-61 [16951180.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):417-27 [17367064.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1293-301 [17375044.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Tissue Antigens. 2007 Jun;69(6):602-6 [17498271.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Surg Neurol. 2007 Aug;68(2):133-43; discussion 143-4 [17537489.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5752-61 [17353902.001]
  • [Cites] Mol Cancer Res. 2007 Sep;5(9):891-7 [17855658.001]
  • [Cites] J Mol Neurosci. 2007;32(1):53-63 [17873288.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2524-33 [17628016.001]
  • [Cites] Stem Cells Dev. 2007 Oct;16(5):837-47 [17999604.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):761-8 [17955491.001]
  • [Cites] Cell. 2009 May 15;137(4):606-8 [19450510.001]
  • [Cites] Stem Cells. 2009 Jan;27(1):40-8 [18948646.001]
  • [Cites] J Neurosci. 2009 Jul 15;29(28):8884-96 [19605626.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):646-50 [9044841.001]
  • [Cites] Cell. 1997 Feb 7;88(3):287-98 [9039255.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):123-9 [18172261.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):639-43 [18288395.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2241-9 [18381430.001]
  • [Cites] Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5 [18382330.001]
  • [Cites] PLoS One. 2008;3(4):e1936 [18398462.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10958-66 [18292095.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1506-16 [18403753.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] Lab Invest. 2008 Aug;88(8):808-15 [18560366.001]
  • [Cites] Stem Cells. 2008 Aug;26(8):1931-8 [18388306.001]
  • [Cites] Cell Stem Cell. 2008 Sep 11;3(3):265-78 [18786414.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6426-38 [18710938.001]
  • [Cites] PLoS One. 2008;3(11):e3769 [19020659.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8205-12 [19088037.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Nat Med. 2009 Jan;15(1):110-6 [19122659.001]
  • [Cites] Neuro Oncol. 2009 Feb;11(1):9-21 [18812521.001]
  • [Cites] Anticancer Res. 2009 Feb;29(2):597-603 [19331209.001]
  • [Cites] Glia. 2009 May;57(7):724-33 [18985733.001]
  • [Cites] J Neurooncol. 2009 May;93(1):49-60 [19430882.001]
  • [Cites] Neurosurgery. 2009 Aug;65(2):237-49; discussion 249-50; quiz N6 [19625901.001]
  • [Cites] Cancer Treat Rev. 2009 Aug;35(5):403-8 [19369008.001]
  • [Cites] Dev Cell. 2009 Aug;17(2):210-21 [19686682.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6 [10468613.001]
  • [Cites] Nature. 1964 Dec 19;204:1161-3 [14264369.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Neurobiol Dis. 2005 Feb;18(1):218-25 [15649712.001]
  • [Cites] Dev Neurosci. 2004 Mar-Aug;26(2-4):148-65 [15711057.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Eur J Pharmacol. 2005 May 2;514(1):1-15 [15878319.001]
  • [Cites] Genes Dev. 2005 May 15;19(10):1129-55 [15905405.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1438-43 [15964995.001]
  • [Cites] J Neurobiol. 2005 Sep 15;64(4):476-90 [16041742.001]
  • [Cites] Nature. 2005 Oct 6;437(7060):894-7 [16208373.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 2;97(21):1589-600 [16264179.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1107-16 [16436596.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):527-38 [16496386.001]
  • [Cites] J Neurooncol. 2006 May;77(3):273-7 [16614947.001]
  • [Cites] Stem Cells. 2009 Aug;27(8):1722-33 [19544433.001]
  • [Cites] Br J Cancer. 2009 Sep 15;101(6):973-82 [19707201.001]
  • [Cites] Nat Neurosci. 2009 Oct;12(10):1248-56 [19734891.001]
  • [Cites] Mol Cell Neurosci. 2010 Jan;43(1):51-9 [18761091.001]
  • [Cites] Cancer Lett. 2010 Mar 1;289(1):1-10 [19643532.001]
  • [Cites] Int J Biochem Cell Biol. 2010 Mar;42(3):421-4 [19733254.001]
  • [Cites] Toxicol Pathol. 2000 Jan-Feb;28(1):193-201 [10669007.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Glia. 2001 Apr 1;34(1):1-7 [11284014.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Acta Neuropathol. 2001 Apr;101(4):334-40 [11355304.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8281-6 [11781843.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):472-8 [11914625.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] J Neurosci Res. 2002 Sep 15;69(6):976-86 [12205691.001]
  • (PMID = 20045420.001).
  • [ISSN] 1873-7064
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS052738-04; United States / NINDS NIH HHS / NS / R01 NS052738; United States / NINDS NIH HHS / NS / NS042925-07; United States / NINDS NIH HHS / NS / R01 NS042925-07; United States / NINDS NIH HHS / NS / R01 NS042925; United States / NINDS NIH HHS / NS / NS052738-04; United States / NINDS NIH HHS / NS / R01NS42925-07; United States / NCI NIH HHS / CA / 1R01 CA129489-01; United States / NCI NIH HHS / CA / R01 CA129489; United States / NINDS NIH HHS / NS / R01NS052738-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Number-of-references] 118
  • [Other-IDs] NLM/ NIHMS168590; NLM/ PMC2839061
  •  go-up   go-down


93. Qiu J, Ai L, Ramachandran C, Yao B, Gopalakrishnan S, Fields CR, Delmas AL, Dyer LM, Melnick SJ, Yachnis AT, Schwartz PH, Fine HA, Brown KD, Robertson KD: Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest; 2008 Sep;88(9):910-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
  • Malignant gliomas are the most common primary brain tumors in adults and the second most common tumor in children.
  • Morbidity and mortality are high in glioma patients because tumors are resistant to treatment and are highly invasive into surrounding brain tissue rendering complete surgical resection impossible.
  • In our previous studies we identified cystatin E/M (CST6) as a frequent target of epigenetic silencing in glioma.
  • Cystatin E/M is a potent inhibitor of cathepsin B, which is frequently overexpressed in glioma.
  • Here, we study the expression of cystatin E/M in normal brain and show that it is highly and moderately expressed in oligodendrocytes and astrocytes, respectively, but not in neurons.
  • In contrast, 78% of 28 primary brain tumors demonstrated reduced/absent cystatin E/M expression using a tissue microarray and this reduced expression correlated with CST6 promoter hypermethylation.
  • Interestingly, CST6 was expressed in neural stem cells (NSC) and markedly induced upon differentiation, whereas a glioma tumor initiating cell (TIC) line was completely blocked for CST6 expression by promoter methylation.
  • Analysis of primary pediatric brain tumor-derived lines also showed CST6 downregulation and methylation in nearly 100% of 12 cases.
  • Finally, ectopic expression of cystatin E/M in glioma lines reduced cell motility and invasion.
  • These results demonstrate that epigenetic silencing of CST6 is frequent in adult and pediatric brain tumors and occurs in TICs, which are thought to give rise to the tumor.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Apr 28;235(2):159-76 [15893421.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] J Biol Chem. 2006 Jun 9;281(23):15893-9 [16565075.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Neuron. 2000 Nov;28(2):385-97 [11144350.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3665-73 [11439329.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):922-34 [12065604.001]
  • [Cites] J Neurooncol. 2002 May;58(1):21-32 [12160137.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7899-909 [16912163.001]
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1429-39 [17081116.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1233-42 [17043665.001]
  • [Cites] Carcinogenesis. 2006 Dec;27(12):2409-23 [16952911.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2621-34 [17043644.001]
  • [Cites] Oncogene. 2007 May 10;26(21):3089-94 [17099723.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):447-60 [17610375.001]
  • [Cites] Nat Protoc. 2007;2(9):2265-75 [17853883.001]
  • [Cites] Biochim Biophys Acta. 2007 Dec;1776(2):125-37 [17868999.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):69-80 [18167341.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):21-30 [18184972.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):655-60 [12684707.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):203-15 [15674478.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):175-82 [16356477.001]
  • [Cites] Life Sci. 2006 Jan 18;78(8):898-907 [16150465.001]
  • [Cites] Nat Rev Genet. 2002 Sep;3(9):662-73 [12209141.001]
  • [Cites] Brain Tumor Pathol. 2002;19(1):15-22 [12455884.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8705-12 [12483523.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):327-30 [12591989.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] J Pediatr Nurs. 2003 Apr;18(2):96-102 [12720206.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):134-42 [12850376.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1911-9 [14578190.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] J Neurosci Res. 2003 Dec 15;74(6):838-51 [14648588.001]
  • [Cites] Neurol Clin. 2003 Nov;21(4):897-913 [14743655.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2206-15 [14676833.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2224-30 [14730346.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Mol Cell. 2004 Apr 23;14(2):207-19 [15099520.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):118-31 [15313584.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6957-64 [15466187.001]
  • [Cites] Development. 1989 Feb;105(2):387-400 [2680425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):285-90 [7542317.001]
  • [Cites] Neurosci Lett. 1996 Apr 26;208(3):171-4 [8733297.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Clin Exp Metastasis. 1996 Sep;14(4):344-50 [8878408.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10853-8 [9099741.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Nature. 1998 Sep 3;395(6697):89-93 [9738504.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):798-802 [10029065.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6665-74 [16818640.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):159-73 [16442709.001]
  • (PMID = 18607344.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114229-04; United States / NCI NIH HHS / CA / R01 CA114229-03; United States / NCI NIH HHS / CA / R01 CA114229; United States / NCI NIH HHS / CA / CA114229-03; United States / NCI NIH HHS / CA / R01CA102289; United States / NCI NIH HHS / CA / R01 CA102289; United States / NCI NIH HHS / CA / CA114229-04; United States / NCI NIH HHS / CA / R01CA114229
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CST6 protein, human; 0 / Cystatin M; 0 / Cystatins; 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS59304; NLM/ PMC2574902
  •  go-up   go-down


94. Rosenthal MA, Ashley DM, Drummond KJ, Dally M, Murphy M, Cher L, Thursfield V, Giles GG: Brain stem gliomas: patterns of care in Victoria from 1998-2000. J Clin Neurosci; 2008 Mar;15(3):237-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain stem gliomas: patterns of care in Victoria from 1998-2000.
  • This study describes the management of and outcomes for adult and paediatric patients with newly diagnosed brain stem gliomas during 1998-2000 in Victoria.
  • Adult patients were identified in a retrospective cohort study conducted by surveying doctors involved in managing incident brainstem glioma cases identified from the population-based Victorian Cancer Registry.
  • Paediatric cases were identified from a retrospective analysis of the Victorian Paediatric Brain tumour database for the same period.
  • Ten adult and 14 paediatric patients were considered eligible for this study.
  • No adult patients and only eight (57%) paediatric patients received chemotherapy.
  • The median survivals for adult patients, paediatric patients with pontine lesions and paediatric patients with non-pontine lesions were: 57, 10 and 60+ months respectively.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery. Neurosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Registries / statistics & numerical data. Retrospective Studies. Survival Rate. Tomography, X-Ray. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226529.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


95. Li KW, Roonprapunt C, Lawson HC, Abbott IR, Wisoff J, Epstein F, Jallo GI: Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas. Neurosurg Focus; 2005 Jun 15;18(6A):E2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Tectal gliomas are a distinct form of pediatric brainstem tumor that present in patients with symptoms related to increased intracranial pressure due to obstructive hydrocephalus.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Endoscopy / methods. Glioma / surgery. Hydrocephalus / surgery. Ventriculostomy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048288.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Lim JY, Park SH, Jeong CH, Oh JH, Kim SM, Ryu CH, Park SA, Ahn JG, Oh W, Jeun SS, Chang JW: Microporation is a valuable transfection method for efficient gene delivery into human umbilical cord blood-derived mesenchymal stem cells. BMC Biotechnol; 2010;10:38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microporation is a valuable transfection method for efficient gene delivery into human umbilical cord blood-derived mesenchymal stem cells.
  • BACKGROUND: Mesenchymal stem cells (MSCs) are an attractive source of adult stem cells for therapeutic application in clinical study.
  • In this study, we applied microporation technology as a novel electroporation technique to introduce enhanced green fluorescent protein (EGFP) and brain-derived neurotropfic factor (BDNF) plasmid DNA into human umbilical cord blood-derived MSCs (hUCB-MSCs) with significant efficiency, and investigated the stem cell potentiality of engineered MSCs through their phenotypes, proliferative capacity, ability to differentiate into multiple lineages, and migration ability towards malignant glioma cells.
  • Gene delivery by microporation may enhance the feasibility of transgenic stem cell therapy.
  • [MeSH-minor] Animals. Brain-Derived Neurotrophic Factor / genetics. Cell Differentiation. Cell Movement. Cell Proliferation. Cells, Cultured. Fetal Blood / cytology. Genes, Reporter. Green Fluorescent Proteins / genetics. Humans. Male. Plasmids. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Neurosci Res. 1999 Jan;33(1):71-8 [10096474.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 [15523088.001]
  • [Cites] Exp Neurol. 2005 Feb;191(2):344-60 [15649491.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3307-18 [15833864.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 5;1724(3):270-80 [15951114.001]
  • [Cites] Acta Neurochir (Wien). 2005 Sep;147(9):985-92; discussion 992 [16010451.001]
  • [Cites] Cloning Stem Cells. 2005;7(3):154-66 [16176125.001]
  • [Cites] Curr Drug Deliv. 2004 Apr;1(2):153-63 [16305381.001]
  • [Cites] Exp Hematol. 2006 Apr;34(4):433-42 [16569590.001]
  • [Cites] Bone Marrow Transplant. 2007 Oct;40(7):609-19 [17603514.001]
  • [Cites] J Neurosci Res. 2008 Aug 1;86(10):2168-78 [18438930.001]
  • [Cites] Mol Ther. 2009 Feb;17(2):302-8 [19066595.001]
  • [Cites] Neuroreport. 2004 Aug 6;15(11):1731-4 [15257137.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):49-52 [10615126.001]
  • [Cites] J Gene Med. 1999 Mar-Apr;1(2):121-33 [10738576.001]
  • [Cites] Bioelectrochemistry. 2001 Jan;53(1):1-10 [11206915.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):861-70 [11387052.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(11):581-8 [11760145.001]
  • [Cites] Cell Transplant. 2002;11(3):265-74 [12075992.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3603-8 [12097260.001]
  • [Cites] Hum Gene Ther. 2002 Jul 20;13(11):1337-47 [12162816.001]
  • [Cites] Neurology. 2002 Aug 27;59(4):514-23 [12196642.001]
  • [Cites] Scand J Immunol. 2003 Jan;57(1):11-20 [12542793.001]
  • [Cites] Mol Ther. 2003 Mar;7(3):354-65 [12668131.001]
  • [Cites] Mol Membr Biol. 2003 Jan-Mar;20(1):35-43 [12745924.001]
  • [Cites] Annu Rev Biochem. 2003;72:609-42 [12676795.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):224-8 [14712307.001]
  • [Cites] Mol Ther. 2004 Feb;9(2):189-97 [14759803.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14835-40 [15466696.001]
  • [Cites] Cytotherapy. 2004;6(5):476-86 [15512914.001]
  • [Cites] Biotechniques. 1990 Jan;8(1):16-20 [2182073.001]
  • [Cites] J Orthop Res. 1991 Sep;9(5):641-50 [1870029.001]
  • [Cites] J Neurosci. 1995 Aug;15(8):5765-78 [7643217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11382-8 [8876144.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4262-7 [10200250.001]
  • (PMID = 20462460.001).
  • [ISSN] 1472-6750
  • [Journal-full-title] BMC biotechnology
  • [ISO-abbreviation] BMC Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC2883955
  •  go-up   go-down


97. Santra M, Katakowski M, Zhang RL, Zhang ZG, Meng H, Jiang F, Chopp M: Protection of adult mouse progenitor cells and human glioma cells by de novo decorin expression in an oxygen- and glucose-deprived cell culture model system. J Cereb Blood Flow Metab; 2006 Oct;26(10):1311-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of adult mouse progenitor cells and human glioma cells by de novo decorin expression in an oxygen- and glucose-deprived cell culture model system.
  • We employed an in vitro hypoxia cell culture model system and gene transfer technology to examine the effect of the decorin gene on cell survival against oxygen and glucose deprivation (OGD).
  • Ectopic expression of decorin in subventricular zone (SVZ) cells from adult male mouse brain and human glioblastoma U-87 cells kept the cells viable against 24 h of OGD.
  • Therefore, our data suggest that decorin is a potent trophic factor that protects neuronal progenitor cells and glioma cells from OGD.
  • [MeSH-major] Aging / physiology. Extracellular Matrix Proteins / metabolism. Glioma / metabolism. Glioma / pathology. Glucose / deficiency. Oxygen / metabolism. Proteoglycans / metabolism. Stem Cells / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467781.001).
  • [ISSN] 0271-678X
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS23393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DCN protein, human; 0 / Dcn protein, mouse; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / ras Proteins; IY9XDZ35W2 / Glucose; S88TT14065 / Oxygen
  •  go-up   go-down


98. Korones DN, Smith A, Foreman N, Bouffet E: Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer; 2006 Jul;47(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses included recurrent brain stem glioma (2), recurrent anaplastic astrocytoma (2), and glioblastoma (7) (3 treatment-induced, 2 malignant transformations of lower grade tumors, 1 recurrence, and 1 second tumor arising 10 months after diagnosis of medulloblastoma).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Child. Child, Preschool. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16047359.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


99. Okamoto K, Furusawa T, Ishikawa K, Sasai K, Tokiguchi S: Focal T2 hyperintensity in the dorsal brain stem in patients with vestibular schwannoma. AJNR Am J Neuroradiol; 2006 Jun-Jul;27(6):1307-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal T2 hyperintensity in the dorsal brain stem in patients with vestibular schwannoma.
  • BACKGROUND AND PURPOSE: The vestibular nucleus cannot be visualized on MR imaging, but some patients with vestibular schwannoma show a tiny area of hyperintensity in the dorsal brain stem on T2-weighted images.
  • METHODS: We retrospectively reviewed the postoperative MR images of 53 patients with cerebellopontine angle tumor.
  • Surgical and histopathologic diagnosis was vestibular schwannoma (41/53 = 77%), meningioma (7/53 = 13%), epidermoid cyst (3/53 = 6%), glioma with exophytic growth (1/53 = 2%), and chordoma (1/53 = 2%).
  • If such hyperintensity is seen in a patient with a large cerebellopontine angle tumor, a diagnosis of vestibular schwannoma is suggested.
  • [MeSH-major] Brain Stem / pathology. Magnetic Resonance Imaging. Neuroma, Acoustic / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Cerebellopontine Angle. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775286.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Kumar AJ, Leeds NE, Kumar VA, Fuller GN, Lang FF, Milas Z, Weinberg JS, Ater JL, Sawaya R: Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas. J Comput Assist Tomogr; 2010 Jul;34(4):601-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas.
  • METHODS: One hundred patients referred to the cancer center with brain tumors histologically proven to be PA were retrospectively reviewed (95 by magnetic resonance imaging and 5 by computed tomographic imaging) and analyzed.
  • Tumor locations consisted of the following: optic chiasm (22), lateral ventricle (3), thalamus (12), basal ganglia (1), cerebral hemisphere (10), corpus callosum (2), brain stem (26), fourth ventricle (1), and cerebellum (23).
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Brain / pathology. Brain / radiography. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed / methods. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657231.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement